Karolin Trautmann‐Grill

Author

University Hospital Carl Gustav Carus ORCID

Also Known As

E. Gökkurt, K Trautmann-Grill, K. Trautmann-Grill, K. Trautmann‐Grill, Karolin Trautmann, Karolin Trautmann-Grill, Karolin Trautmann‐Grill

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University Hospital Carl Gustav Carus Goethe University Frankfurt University Medical Center Hamburg-Eppendorf Universität Hamburg Technische Universität Dresden

About

Karolin Trautmann‐Grill is an author at University Hospital Carl Gustav Carus specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	631
2	Cellular Therapies	3	3	250
3	Health Sciences	1	1	22
4	Allergy	1	1	53
5	Cell Biology	1	1	175

Karolin Trautmann‐Grill

Publications

942

Citations

H-Index

Page 1

	Year	Citations
Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease Anke Theil, Sebastian Tuve, Uta Oelschlägel, Cytotherapy Cell TherapyTransplantationAutoimmune DiseaseT-regulatory CellStem Cell Transplantation	2015	175
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, The Lancet Hematological MalignancyBone Marrow FailureMomelotinib Versus DanazolSymptomatic PatientsHematology	2023	164
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial Hartmut Goldschmidt, K. Elias, Uta Bertsch, The Lancet Haematology Transplantation-eligible PatientsHematological MalignancyPart 1TransplantationMedicine	2022	142
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial Paul J. Bröckelmann, Ina Bühnen, Karolin Trautmann‐Grill, Journal of Clinical Oncology	2022	78
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study Andreas Tiede, Christina Hart, Paul Knöbl, The Lancet Haematology AllergyHematologyBleeding DisorderPhase 2Emicizumab Prophylaxis	2023	53
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment Raphael Teipel, Frank Kroschinsky, Michael Krämer, Blood Advances Chimeric Antigen ReceptorLymphoid NeoplasiaCell TherapyAutoimmune DiseaseMedicine	2022	49
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial K. Elias, Uta Bertsch, Ema Požek, Journal of Clinical Oncology	2024	48
A phase 2 clinical trial of combined BRAF/MEK inhibition for <i>BRAF</i>V600E-mutated multiple myeloma Nicola Giesen, Manik Chatterjee, Christof Scheid, Blood	2023	43
Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial Conrad‐Amadeus Voltin, Jasmin Mettler, Lutz van Heek, Clinical Cancer Research	2020	41
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial Hartmut Goldschmidt, K. Elias, Eva Nievergall, Blood	2021	32

Page 1